Navigation Links
Monogram Announces 2008 Third Quarter Financial Results
Date:10/27/2008

icer. "While reported gross margin on product revenues for the third quarter was 51%, adjusted for the deferral of $1.6 million in revenues related to our Pfizer collaboration, gross margin would have been 55%."

The Company had approximately $21.8 million in cash and cash equivalents at September 30, 2008. Cash used in operations for the first nine months of 2008 was $13.0 million.

HIV Tropism Testing

"Monogram's enhanced Trofile Assay, introduced earlier this year with a thirty-fold improvement in sensitivity, has allowed a very important new analysis of Pfizer Inc.'s phase III trial of Selzentry(TM) (maraviroc) in treatment naive individuals with CCR5-tropic HIV-1, known as the 'MERIT' study," said William Young, Monogram chief executive officer. "Data reported this week by Pfizer demonstrated that in this study, increased efficacy was shown as a result of the enrichment of the patient population by use of the enhanced version of Monogram's Trofile(TM) Assay." Results of the reanalysis of the "MERIT" trial were reported this week at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington DC.

Pfizer's HIV medication Selzentry (maraviroc) is approved for use in treatment-experienced individuals with R5-tropic HIV-1. In July 2007 Pfizer reported data from the phase III trial of Selzentry in treatment naive individuals ("MERIT"), in which patients had been selected for treatment by Monogram's Trofile Assay. The reported differences in outcome for individuals treated with Selzentry did not meet a predefined study endpoint of non-inferiority to an established first line treatment regimen. To week 48, 65% of individuals receiving Selzentry had HIV-1 RNA <50 copies/mL, compared to 69% of those individuals in the control arm of the trial.

In June 2008 Monogram introduced an enhanced sensitivity version of the Trofile Assay, with 30-fold greater sensitivity to detect low-level X4 HIV compared
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
10. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... India’s vast and growing population means ... up to a billion dollars per year by ... taking serious action to better regulate and oversee ... will examine:, ,     Recent changes in ... long term impacts ,     Foreseeable opportunities ...
(Date:6/19/2013)... 19, 2013 Express Diagnostics Int’l, Inc., ... announced that it has received Class III medical device ... its DrugCheck® NxStep Onsite Drug Screen Cup ... rapid screening device in near-patient settings, such as physicians’ ... received Health Canada Class III approval for 24 different ...
(Date:6/18/2013)... 2013) A million electric cars could be on roads ... the help of research by the United States Department of ... , Professor Zhongwei Chen is part of a team led ... materials to replace the expensive platinum catalysts in fuel cells. ... fuel cells in vehicles is the cost of the units. ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 (PRWEB) June 18, 2013 ... time and attendance system in North America, has ... shares employee data and payroll records between ExakTime’s ... Plus automates ExakTime software setup and keeps ... imports employee data from a business’ current payroll ...
Breaking Biology Technology:Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3US and Canadian researchers drive towards cheaper fuel cells for electric cars 2ExakTime Introduces AccountLinx Plus 2
... VALLEY COTTAGE, N.Y., March 11 XTL Biopharmaceuticals Ltd. (Nasdaq: ... Extraordinary General Meetings ("EGMs") were postponed for one week in ... of a quorum. The postponed EGMs will take place at ... 76100 at 3:00 p.m. and 5:30 p.m. Israel time on ...
... (NYSE Alternext US: DDD) today reported financial results for ... The Company will host a live conference call ... Time)."Last year was an important period for SCOLR Pharma," ... "Utilizing our unique CDT(R) platforms, we made significant progress ...
... LANSING, Mich., March 11 Neogen Corporation (Nasdaq: ... Neogen Corporation 3rd Quarter Results WebcastWhen: ... http://www.videonewswire.com/event.asp?id=56632 How: Live over the ... at the address above. Contact: Terry ...
Cached Biology Technology:SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 2SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 3SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 4SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 5SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 6SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 7SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 8
(Date:6/18/2013)... DNA and this modification can occur in millions ... scientists believed that this epigenetic phenomenon actively reduced ... of researchers from the University of Geneva (UNIGE), ... the Faculty of Medicine, reveals that this is ... may play both a passive and active role ...
(Date:6/17/2013)... have identified a new virus in patients with severe ... determine whether the virus is responsible for the symptoms ... total of 28 out of 644 patients with severe ... but not in any of the 122 patients with ... the brain and central nervous system are often fatal ...
(Date:6/17/2013)... understand the concept of improving original foundations with more ... the University of Pittsburgh,s Kenneth P. Dietrich School of ... that could make drug delivery, gas storage, and gas ... findings were reported in the latest issue of the ... JACS ). , The recent work builds upon Pitt ...
Breaking Biology News(10 mins):The secret of DNA methylation 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
... A new University of Central Florida study will examine how ... the Florida Panhandle and Alabama and Mississippi coasts. The ... Civil Engineering, is a response to scientific studies that show ... Hagen,s research also could potentially be linked with models of ...
... free of charge so that customers can neutralise the heart ... suggest in a new study published this week. Statins ... A wealth of trial data has proven them to be ... In a paper published in the Sunday 15 August issue ...
... Mount Sinai School of Medicine, New York, has been ... receive a 2010 ICAAC Young Investigator Award. Sponsored ... an early career scientist for research excellence in microbiology ... postdoctoral training in Molecular Biology at Harvard University in ...
Cached Biology News:Study to examine rising sea level's impact on estuaries, coastal communities 2Free statins with fast food could neutralize heart risk, scientists say 2
... frozen Sf9 Insect Cells are derived from the ... for optimal growth, use in transfections, plaque assays, ... frozen in a protocol that optimizes recovery of ... growth in serum-free BacVector Insect Cell Medium and ...
... software package that provides crystallographers with ... buffer creation, set-up of experimental conditions ... The software helps crystallographers through the ... crystallography: Design of ...
... premium quality recombinant form of Thermus aquaticus ... for a wide range of PCR applications. ... performance, each preparation is extensively tested in ... DNA Polymerase possesses an integral 5′→3′ exonuclease ...
... direct antibiotic-based selection system for recombinant identification. ... eliminating the need for costly color screening. ... to 100% accuracy in recombinant selection. pLivSelect ... colony picking. This cloning kit can be ...
Biology Products: